The DOI matches its Crossref record; 366 of the 366 references it cites were found in a registry or an index.
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Open accessAbstract
Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in prostate cancer that facilitates tumor formation, disease progression and therapeutic resistance. Recent discoveries indicate that the complex crosstalk between the PI3K-AKT-mTOR pathway and multiple interacting cell signaling cascades can further promote prostate cancer progression and influence the sensitivity of prostate cancer cells to PI3K-AKT-mTOR-targeted therapies being explored in the clinic, as well as standard treatment approaches such as androgen-deprivation therapy (ADT). However, the full extent of the PI3K-AKT-mTOR signaling network during prostate tumorigenesis, invasive progression and disease recurrence remains to be determined. In this review, we outline the emerging diversity of the genetic alterations that lead to activated PI3K-AKT-mTOR signaling in prostate cancer, and discuss new mechanistic insights into the interplay between the PI3K-AKT-mTOR pathway and several key interacting oncogenic signaling cascades that can cooperate to facilitate prostate cancer growth and drug-resistance, specifically the androgen receptor (AR), mitogen-activated protein kinase (MAPK), and WNT signaling cascades. Ultimately, deepening our understanding of the broader PI3K-AKT-mTOR signaling network is crucial to aid patient stratification for PI3K-AKT-mTOR pathway-directed therapies, and to discover new therapeutic approaches for prostate cancer that improve patient outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–366 of 366
Zhang, Y., Gan, B., Liu, D., & Paik, J.-H. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.15954 · Cited by 167
Taniguchi, C. M., Winnay, J., Kondo, T., Bronson, R. T., Guimaraes, A. R., Alemán, J. O., Luo, J., Stephanopoulos, G., Weissleder, R., Cantley, L. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3399 · Cited by 166
Sestrin2 as a Novel Biomarker and Therapeutic Target for Various Diseases
Pasha, M., Eid, A. H., Eid, A. A., Gorin, Y. C., & Munusamy, S. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3296294 · Cited by 166
Wang, Q., Bailey, C. G., Ng, C., Tiffen, J., Thoeng, A., Minhas, V., Lehman, M. L., Hendy, S. C., Buchanan, G., Nelson, C. C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1821 · Cited by 165
Shi, Y., Sharma, A., Wu, H., Lichtenstein, A. K., & Gera, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m407874200 · Cited by 165
Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways
Santinon, G., Pocaterra, A., & Dupont, S. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.11.004 · Cited by 165
Wu, L., Birle, D. C., & Tannock, I. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3137 · Cited by 164
Han, Y., Hu, Z., Cui, A., Liu, Z., Ma, F., Xue, Y., Liu, Y., Zhang, F., Zhao, Z., Yu, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08585-4 · Cited by 164
Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)
TOREN, P., & ZOUBEIDI, A. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2601 · Cited by 163
AR Signaling and the PI3K Pathway in Prostate Cancer
Crumbaker, M., Khoja, L., & Joshua, A. (2017) · Cancers · doi:10.3390/cancers9040034 · Cited by 162
Liu, H., Yin, J., Wang, H., Jiang, G., Deng, M., Zhang, G., Bu, X., Cai, S., Du, J., & He, Z. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.01.001 · Cited by 161
Molecular Pathways: Is AMPK a Friend or a Foe in Cancer?
Hardie, D. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3300 · Cited by 161
Lysosomal recruitment of TSC2 is a universal response to cellular stress
Demetriades, C., Plescher, M., & Teleman, A. A. (2016) · Nature Communications · doi:10.1038/ncomms10662 · Cited by 160
Second AKT: The rise of SGK in cancer signalling
Bruhn, M. A., Pearson, R. B., Hannan, R. D., & Sheppard, K. E. (2010) · Growth Factors · doi:10.3109/08977194.2010.518616 · Cited by 160
Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
Rajan, P., Sudbery, I. M., Villasevil, M. E. M., Mui, E. J., Fleming, J., Davis, M., Ahmad, I., Edwards, J., Sansom, O. J., Sims, D., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.011 · Cited by 159
Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.
Han, S., Kato, H., Kato, S., Suzuki, T., Shibata, H., Ishii, S., Shiiba, K.-I., Matsuno, S., Kanamaru, R., & Ishioka, C. (2000) · PubMed · Cited by 158
Regulation and cellular functions of class II phosphoinositide 3-kinases
Falasca, M., & Maffucci, T. (2012) · Biochemical Journal · doi:10.1042/bj20120008 · Cited by 158
Sestrin2 promotes LKB1‐mediated AMPK activation in the ischemic heart
Morrison, A., Chen, L., Wang, J., Zhang, M., Yang, H., Ma, Y., Budanov, A., Lee, J. H., Karin, M., & Li, J. (2015) · The FASEB Journal · doi:10.1096/fj.14-258814 · Cited by 157
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Conciatori, F., Ciuffreda, L., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., & Milella, M. (2018) · Cancers · doi:10.3390/cancers10010023 · Cited by 157
Zhang, Z., Cheng, L., Li, J., Farah, E., Atallah, N. M., Pascuzzi, P. E., Gupta, S., & Liu, X. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3006 · Cited by 157
Phosphatidylinositol 3-Kinase Signaling Does Not Activate the Wnt Cascade
Ng, S. S., Mahmoudi, T., Danenberg, E., Bejaoui, I., de Lau, W., Korswagen, H. C., Schutte, M. E. M., & Clevers, H. C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.078261 · Cited by 153
Steele, C. B., Li, J., Huang, B., & Weir, H. K. (2017) · Cancer · doi:10.1002/cncr.31026 · Cited by 153
Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer
Hodgson, M. C., Shao, L.-J., Frolov, A., Li, R., Peterson, L. E., Ayala, G., Ittmann, M., Weigel, N. L., & Agoulnik, I. U. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2314 · Cited by 152
Audet‐Walsh, É., Dufour, C. R., Yee, T., Zouanat, F. Z., Yan, M., Kalloghlian, G., Vernier, M., Caron, M., Bourque, G., Scarlata, E., et al. (2017) · Genes & Development · doi:10.1101/gad.299958.117 · Cited by 151
Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150 · cited 1×
“, AKT and SRC) can also independently stimulate AR dependent transcriptional activity when androgen levels are low, which can facilitate therapeutic resistance to androgen/AR blockade [12,281,287].”
BackgroundSGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
Gasser, J. A., Inuzuka, H., Lau, A. W., Wei, W., Beroukhim, R., & Toker, A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.023 · Cited by 149
Chapter 3 Ribosomal Protein S6 Kinase
Meyuhas, O., & Dreazen, A. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)90003-5 · Cited by 148
Thomas, C., Lamoureux, F., Crafter, C., Davies, B. R., Beraldi, E., Fazli, L., Kim, S., Thaper, D., Gleave, M. E., & Zoubeidi, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0032 · Cited by 147
Activation of Phosphoinositide 3-Kinase γ by Ras
Suire, S., Hawkins, P. T., & Stephens, L. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00933-8 · Cited by 143
Maurer, M. S., Su, T., Saal, L. H., Koujak, S., Hopkins, B. D., Barkley, C. R., Wu, J., Nandula, S. V., Dutta, B., Xie, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0820 · Cited by 143
Kluth, M., Hesse, J., Heinl, A., Krohn, A., Steurer, S. A., Sirma, H., Simon, R., Mayer, P.-S., Schumacher, U., Grupp, K., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2012.236 · Cited by 142
Hayashi, M., Tapping, R. I., Chao, T.-H., Lo, J., King, C. C., Yang, Y. C., & Lee, J.-D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000838200 · Cited by 141
Pearson, H. B., Li, J., Méniel, V. S., Fennell, C. M., Waring, P. M., Montgomery, K. G., Rebello, R. J., Macpherson, A. A., Koushyar, S., Furic, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0867 · Cited by 141
Self-citationThe p90 RSK Family Members: Common Functions and Isoform Specificity
Lara, R., Seckl, M. J., & Pardo, O. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4448 · Cited by 140
Butler, D. E., Marlein, C. R., Walker, H. F., Frame, F. M., Mann, V. M., Simms, M. S., Davies, B. R., Collins, A. T., & Maitland, N. J. (2017) · Oncotarget · doi:10.18632/oncotarget.18082 · Cited by 138
Soares, H. P., Ni, Y., Kisfalvi, K., Sinnett‐Smith, J. W., & Rozengurt, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057289 · Cited by 136
Control of Axonal Growth and Regeneration of Sensory Neurons by the p110δ PI 3-Kinase
Eickholt, B. J., Ahmed, A. I., Davies, M., Papakonstanti, E. A., Pearce, W. P., Starkey, M. L., Bilancio, A., Need, A. C., Smith, A. J. H., Hall, S. M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000869 · Cited by 135
Yao, E. S., Zhou, W., Lee-Hoeflich, S. T., Truong, T., Haverty, P. M., Eastham‐Anderson, J., Lewin‐Koh, N., Gunter, B., Belvin, M. P., Murray, L. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2814 · Cited by 134
Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells
Gocher, A. M., Azabdaftari, G., Euscher, L. M., Dai, S., Karacosta, L. G., Franke, T. F., & Edelman, A. M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.778464 · Cited by 134
Mehenni, H., Lin-Marq, N., Buchet-Poyau, K., Reymond, A., Collart, M. A., Picard, D., & Antonarakis, S. E. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi225 · Cited by 132
Zhang, L., Huang, J., Yang, N., Greshock, J. D., Liang, S., Hasegawa, K., Giannakakis, A., Poulos, N., O’Brien-Jenkins, A., Katsaros, D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2660 · Cited by 131
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
Jokinen, E., & Koivunen, J. P. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015571111 · Cited by 128
Ooms, L. M., Binge, L. C., Davies, E. M., Rahman, P., Conway, J. R. W., Gurung, R., Ferguson, D. T., Papa, A., Fedele, C. G., Vieusseux, J. L., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.003 · Cited by 127
Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer
Liao, Y., Grobholz, R., Abel, U. R., Trojan, L., Michel, M. S., Angel, P. E., & Mayer, D. (2003) · International Journal of Cancer · doi:10.1002/ijc.11471 · Cited by 127
SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway
Liu, W., Wang, X., Liu, Z., Wang, Y., Yin, B., Pan, Y., Duan, X., Liao, Z., Chen, Y., Liu, C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.293 · Cited by 127
Raiborg, C., Schink, K. O., & Stenmark, H. (2013) · FEBS Journal · doi:10.1111/febs.12116 · Cited by 125
Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells
Yang, X., Chen, M.-W., Terry, S., Vacherot, F., Bemis, D. L., Capodice, J. L., Kitajewski, J., TAILLE, A. D. L., Benson, M. C., Guo, Y., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209366 · Cited by 123
Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signaling
Aznar, N., Midde, K., Dunkel, Y., López-Sánchez, I., Pavlova, Y., Marivin, A., Barbazán, J., Murray, F., Nitsche, U., Janssen, K., et al. (2015) · eLife · doi:10.7554/elife.07091 · Cited by 122
Ma, L., Teruya‐Feldstein, J., Behrendt, N., Chen, Z., Noda, T., Hino, O., Cordon‐Cardo, C., & Pandolfi, P. P. (2005) · Genes & Development · doi:10.1101/gad.1314405 · Cited by 121
Revisiting the role of Wnt/β-catenin signaling in prostate cancer
Schneider, J. A., & Logan, S. K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.008 · Cited by 121
Ho, D. W., Chan, L., Chiu, Y. T., Xu, M., Poon, R. T. P., Cheung, T. T., Tang, C. N., Tang, V. W., Lo, I. L., Lam, P. W. Y., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-312734 · Cited by 120
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer
Rebello, R. J., Pearson, R. B., Hannan, R. D., & Furic, L. (2017) · Genes · doi:10.3390/genes8020071 · Cited by 118
PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α
Thorpe, L. M., Spangle, J. M., Ohlson, C. E., Cheng, H.-L. M., Roberts, T. M., Cantley, L. C., & Zhao, J. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704706114 · Cited by 116
Wang, B., Ceniccola, K., Hwang, S., Andrawis, R., Horvath, A., Freedman, J. A., Olender, J., Knapp, S., Ching, T. H., Garmire, L. X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15921 · Cited by 112
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases
Rodgers, S. J., Ferguson, D. T., Mitchell, C. A., & Ooms, L. M. (2017) · Bioscience Reports · doi:10.1042/bsr20160432 · Cited by 110
Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Bruxvoort, K. J., Charbonneau, H. M., Giambernardi, T. A., Goolsby, J. C., Qian, C.-N., Diegel, C. R., Robinson, D. R., Roy‐Burman, P., Shaw, A. K., Buckner-Berghuis, B. D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3028 · Cited by 108
Ratnacaram, C. K., Teletin, M., Jiang, M., Meng, X., Chambon, P., & METZGER, D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712021105 · Cited by 108
Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation
Wall, M., Poortinga, G., Hannan, K. M., Pearson, R. B., Hannan, R. D., & McArthur, G. A. (2008) · Blood · doi:10.1182/blood-2007-09-111856 · Cited by 106
The receptor tyrosine kinase ROR1 – An oncofetal antigen for targeted cancer therapy
Hojjat‐Farsangi, M., Moshfegh, A., Daneshmanesh, A. H., Khan, A. S., Mikaelsson, E., Österborg, A., & Mellstedt, H. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.005 · Cited by 104
Bago, R., Sommer, E. M., Castel, P., Crafter, C., Bailey, F. P., Shpiro, N., Baselga, J. M., Cross, D. A. E., Eyers, P. A., & Alessi, D. R. (2016) · The EMBO Journal · doi:10.15252/embj.201693929 · Cited by 104
The Dominant Role of Forkhead Box Proteins in Cancer
Bach, D., Long, N. P., Luu, T.-T.-T., Anh, N. H., Kwon, S. W., & Lee, S. K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103279 · Cited by 103
Chew, C. L., Lunardi, A., Gulluni, F., Ruan, D. T., Chen, M., Salmena, L., Nishino, M., Papa, A., Ng, C., Fung, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1347 · Cited by 101
Armstrong, A. J., Halabi, S., Healy, P. N., Alumkal, J. J., Winters, C., Kephart, J. J. G., Bitting, R. L., Hobbs, C. A., Soleau, C., Beer, T. M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.030 · Cited by 101
B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer
Wang, J., Kobayashi, T., Floc’h, N., Kinkade, C. W., Aytés, À., Dankort, D. L., Lefèbvre, C., Mitrofanova, A., Cardiff, R. D., McMahon, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0820 · Cited by 100
Velho, P. I., Fu, W., Wang, H., Mirkheshti, N., Qazi, F., Lima, F., Shaukat, F., Carducci, M. A., Denmeade, S. R., Paller, C. J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.05.032 · Cited by 100
Leucyl-tRNA Synthetase Activates Vps34 in Amino Acid-Sensing mTORC1 Signaling
Yoon, M., Son, K., Arauz, E. J., Han, J. M., Kim, S., & Chen, J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.008 · Cited by 99
Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth
Wang, Q., Zhou, Y., Rychahou, P. G., Harris, J. W., Zaytseva, Y. Y., Liu, J., Wang, C., Weiss, H. L., Liu, C., Lee, E. Y., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3107 · Cited by 99
Yamada, E., Pessin, J. E., Kurland, I. J., Schwartz, G. J., & Bastie, C. C. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.12.010 · Cited by 98
Barfeld, S., Urbanucci, A., Itkonen, H., Fazli, L., Hicks, J., Thiede, B., Rennie, P., Yegnasubramanian, S., Marzo, A. D., & Mills, I. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.006 · Cited by 98
Phosphoinositide Phosphatases: Just as Important as the Kinases
Dyson, J. M., Fedele, C. G., Davies, E. M., Becanovic, J., & Mitchell, C. A. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-3012-0_7 · Cited by 96
K-ras and Wnt Signaling Synergize to Accelerate Prostate Tumorigenesis in the Mouse
Pearson, H. B., Phesse, T. J., & Clarke, A. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2895 · Cited by 94
Self-citationThe emerging role of speckle-type POZ protein (SPOP) in cancer development
Mani, R. S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.07.009 · Cited by 94
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer
Evangelisti, C., Chiarini, F., Paganelli, F., Marmiroli, S., & Martelli, A. M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118635 · Cited by 93
Kolinsky, M. P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.074 · Cited by 92
Griend, D. J. V., Litvinov, I. V., & Isaacs, J. T. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8756 · Cited by 91
Massard, C., Chi, K. N., Castellano, D., Bono, J. S. D., Gravis, G., Dirix, L. Y., Machiels, J., Mita, A. C., Mellado, B., Turri, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.024 · Cited by 91
Lkb1 Deficiency Causes Prostate Neoplasia in the Mouse
Pearson, H. B., McCarthy, A., Collins, C. M. P., Ashworth, A., & Clarke, A. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5169 · Cited by 89
Self-citationBardia, A., Gounder, M. M., Rodon, J. A., Jankú, F., Lolkema, M. P., Stephenson, J., Bedard, P. L., Schüler, M., Sessa, C., LoRusso, P. M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0297 · Cited by 89
INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor
Kofuji, S., Kimura, H., Nakanishi, H., Nanjo, H., Takasuga, S., Liu, H., Eguchi, S., Nakamura, R., Itoh, R., Ueno, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1329 · Cited by 88
Bilanges, B., Alliouachene, S., Pearce, W. P., Morelli, D., Szabadkai, G., Chung, Y.-L., Chicanne, G., Valet, C., Hill, J. M., Voshol, P. J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01969-4 · Cited by 87
SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation
Bilir, B., Osunkoya, A. O., Wiles, W. G., Sannigrahi, S., Lefebvre, V., METZGER, D., Spyropoulos, D. D., Martin, W. D., & Moreno, C. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1868 · Cited by 86
A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity
Conde‐Perez, A., Gros, G., Longvert, C., Pedersen, M., Petit, V., Aktary, Z., Virós, A., Gesbert, F., Delmas, V., Rambow, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms9093 · Cited by 85
Mizuno, H., & Nishida, E. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00418.x · Cited by 85
TSC1 Activates TGF-β-Smad2/3 Signaling in Growth Arrest and Epithelial-to-Mesenchymal Transition
Thien, A., Prentzell, M. T., Holzwarth, B., Kläsener, K., Kuper, I., Boehlke, C. S., Sonntag, A., Ruf, S., Maerz, L. D., Nitschke, R., et al. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.01.026 · Cited by 84
The multiple layers of non-genetic regulation of PTEN tumour suppressor activity
Correia, N., Gírio, A., Antunes, I., Martins, L. R., & Barata, J. T. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.017 · Cited by 83
Meng, F., Yamagiwa, Y., Taffetani, S., Han, J.-H., & Patel, T. (2005) · American Journal of Physiology - Cell Physiology · doi:10.1152/ajpcell.00081.2005 · Cited by 82
Hippo–YAP and mTOR pathways collaborate to regulate organ size
Csibi, A., & Blenis, J. (2012) · Nature Cell Biology · doi:10.1038/ncb2634 · Cited by 81
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling
Berenjeno, I. M., Piñeiro, R., Castillo, S. D., Pearce, W. P., McGranahan, N., Dewhurst, S. M., Méniel, V. S., Birkbak, N. J., Lau, E., Sansregret, L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02002-4 · Cited by 81
Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells
Wang, G., Jones, S. J. M., Marra, M. A., & Sadar, M. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209715 · Cited by 80
Sestrins at the Interface of ROS Control and Autophagy Regulation in Health and Disease
Cordani, M., Sánchez‐Álvarez, M., Strippoli, R., Bazhin, A. V., & Donadelli, M. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/1283075 · Cited by 78
Yang, Y., Blee, A. M., Wang, D., An, J., Pan, Y., Yan, Y., Ma, T., He, Y., Dugdale, J. A., Hou, X., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0686 · Cited by 76
The AMPK β2 Subunit Is Required for Energy Homeostasis during Metabolic Stress
Dasgupta, B., Ju, J.-S., Sasaki, Y., Liu, X., Jung, S.-R., Higashida, K., Lindquist, D. M., & Milbrandt, J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.05853-11 · Cited by 71
Gioeli, D. G., Wunderlich, W., Sebolt, J. S., Bekiranov, S., Wulfkuhle, J. D., Petricoin, E. F., Conaway, M. C., & Weber, M. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1033 · Cited by 71
Saranyutanon, S., Srivastava, S. K., Pai, S. G., Singh, S., & Singh, A. P. (2019) · Cancers · doi:10.3390/cancers12010051 · Cited by 71
Antony, L., van der Schoor, F., Dalrymple, S. L., & Isaacs, J. T. (2014) · The Prostate · doi:10.1002/pros.22828 · Cited by 69
Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice
Shukla, S., Bhaskaran, N., MacLennan, G. T., & Gupta, S. (2013) · The Prostate · doi:10.1002/pros.22698 · Cited by 68
p110δ PI3 kinase pathway: emerging roles in cancer
Tzenaki, N., & Papakonstanti, E. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00040 · Cited by 68
Liu, P., Li, S., Gan, L., Kao, T. P., & Huang, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2038 · Cited by 67
The role of LKB1 in lung cancer
Sánchez‐Céspedes, M. (2011) · Familial Cancer · doi:10.1007/s10689-011-9443-0 · Cited by 67
Lee, S., Poulogiannis, G., Pyne, S., Jia, S., Zou, L., Signoretti, S., Loda, M. F., Cantley, L. C., & Roberts, T. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005642107 · Cited by 67
Recent insights into the biological functions of sestrins in health and disease
Wang, M., Xu, Y., Liu, J., Ye, J., Yuan, W., Jiang, H., Wang, Z., Jiang, H., & Wan, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484060 · Cited by 67
Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
Čulig, Z. (2017) · Current Molecular Biology Reports · doi:10.1007/s40610-017-0079-1 · Cited by 67
The TAK1-NF-κB axis as therapeutic target for AML
Bosman, M. C. J., Schepers, H., Jaques, J., Brouwers-Vos, A. Z., Quax, W. J., Schuringa, J. J., & Vellenga, E. (2014) · Blood · doi:10.1182/blood-2014-04-569780 · Cited by 65
Coactivator selective regulation of androgen receptor activity
Agoulnik, I. U., & Weigel, N. L. (2009) · Steroids · doi:10.1016/j.steroids.2009.02.007 · Cited by 64
HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer
Ahmad, I., Patel, R., Singh, L. B., Nixon, C., Seywright, M. M., Barnetson, R. J., Brunton, V. G., Muller, W. J., Edwards, J., Sansom, O. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101263108 · Cited by 63
Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation
Hoekstra, E., Das, A. M., Willemsen, M., Swets, M., Kuppen, P. J. K., van der Woude, C. J., Bruno, M. J., Shah, J. P., ten Hagen, T. L. M., Chisholm, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12321 · Cited by 63
TAK1 regulates skeletal muscle mass and mitochondrial function
Hindi, S. M., Sato, S., Xiong, G., Bohnert, K. R., Gibb, A., Gallot, Y. S., McMillan, J. D., Hill, B. G., Uchida, S., & Kumar, A. (2018) · JCI Insight · doi:10.1172/jci.insight.98441 · Cited by 63
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Mostaghel, E. A. (2014) · Cancer Management and Research · doi:10.2147/cmar.s39318 · Cited by 62
Su, B., Gao, L., Baranowski, C., Gillard, B. M., Wang, J., Ransom, R., Ko, H., & Gelman, I. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101411 · Cited by 61
CAMKK2 promotes prostate cancer independently of AMPK via increased lipogenesis
Penfold, L., Woods, A., Muckett, P. J., Nikitin, A., Kent, T., Zhang, S., Graham, R. N., Pollard, A. E., & Carling, D. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0585 · Cited by 61
Suppression of Tak1 Promotes Prostate Tumorigenesis
Wu, M., Shi, L., Cimic, A., Romero, L. M., Sui, G., Lees, C. J., Cline, J. M., Seals, D. F., Sirintrapun, J. S., McCoy, T. P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2724 · Cited by 60
Sathe, A., Chalaud, G., Oppolzer, I. A., Wong, K. Y., von Busch, M., Schmid, S. C., Tong, Z., Retz, M. M., Gschwend, J. E., Schulz, W. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190854 · Cited by 60
Tzenaki, N., Andreou, M., Stratigi, K., Vergetaki, A., Makrigiannakis, A., Vanhaesebroeck, B., & Papakonstanti, E. A. (2012) · The FASEB Journal · doi:10.1096/fj.11-198192 · Cited by 58
Choudhury, Y., Yang, Z., Ahmad, I., Nixon, C., Salt, I. P., & Leung, H. Y. (2014) · Oncoscience · doi:10.18632/oncoscience.49 · Cited by 58
Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer
Amato, R. J., Jac, J., Mohammad, T., & Saxena, S. (2008) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2008.n.015 · Cited by 57
Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention
Jia, S., Gao, X., Lee, S., Maira, S.-M., Wu, X., Stack, E. C., Signoretti, S., Loda, M. F., Zhao, J. J., & Roberts, T. M. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0262 · Cited by 57
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform
Gillessen, S., Gilson, C., James, N. D., Adler, A., Sydes, M. R., & Clarke, N. W. (2016) · European Urology · doi:10.1016/j.eururo.2016.07.015 · Cited by 57
Liang, M.-C., Ma, J., Chen, L., Kozłowski, P., Qin, W., Li, D. D., Goto, J., Shimamura, T., Hayes, D. N., Meyerson, M. M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.452 · Cited by 56
Wei, X. X., Hsieh, A. C., Kim, W. K., Friedlander, T. W., Lin, A., Louttit, M., & Ryan, C. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0432 · Cited by 56
Ravitz, M. J., Chen, L., Lynch, M. C., & Schmidt, E. V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4351 · Cited by 54
Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis
Brazzatti, J. A., Klingler‐Hoffmann, M., Haylock‐Jacobs, S., Harata‐Lee, Y., Niu, M., Higgins, M. D., Kochetkova, M., Hoffmann, P., & McColl, S. R. (2011) · Oncogene · doi:10.1038/onc.2011.414 · Cited by 54
Divide and ProsPer: The emerging role of PtdIns3P in cytokinesis
Nezis, I. P., Sagona, A. P., Schink, K. O., & Stenmark, H. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.08.010 · Cited by 52
Interaction of β-Catenin and TIF2/GRIP1 in Transcriptional Activation by the Androgen Receptor
Song, L., & Gelmann, E. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503850200 · Cited by 52
Crabb, S. J., Birtle, A. J., Martin, K., Downs, N., Ratcliffe, I. C., Maishman, T., Ellis, M., Griffiths, G. O., Thompson, S. D., Ksiazek, L., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0433-4 · Cited by 52
NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence
Manda, K. R., Tripathi, P., Hsi, A. C., Ning, J., Ruzinova, M. B., Liapis, H., Bailey, M. H., Zhang, H., Maher, C. A., Humphrey, P. A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.389 · Cited by 51
Conditional Akt activation promotes androgen-independent progression of prostate cancer
Li, B., Sun, A., Youn, H., Hong, Y., Terranova, P. F., Thrasher, J. B., Xu, P., & Spencer, D. M. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl193 · Cited by 51
The PHLPP2 phosphatase is a druggable driver of prostate cancer progression
Nowak, D. G., Cohen‐Katsenelson, K., Watrud, K. E., Chen, M., Mathew, G., D’Andrea, V. D., Lee, M. F., Swamynathan, M. M., Casanova‐Salas, I., Jibilian, M. C., et al. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201902048 · Cited by 51
Qi, W., Morales, C., Cooke, L. S., Johnson, B., Somer, B. G., & Mahadevan, D. (2015) · Oncotarget · doi:10.18632/oncotarget.5659 · Cited by 50
Basnet, R., Gong, G. Q., Li, C., & Wang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.07.001 · Cited by 50
Active β-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A
Persad, A. R. L., Venkateswaran, G., Li, H., Garcia, M. E., Yoon, J., Sidhu, J., & Persad, S. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.128 · Cited by 49
Energy sensing and cancer: LKB1 function and lessons learnt from Peutz–Jeghers syndrome
Shorning, B. Y., & Clarke, A. R. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.02.015 · Cited by 47
Self-citationD'Abronzo, L. S., Bose, S., Crapuchettes, M., Beggs, R. E., Vinall, R. L., Tepper, C. G., Siddiqui, S., Mudryj, M. M., Melgoza, F. U., Durbin-Johnson, B. P., et al. (2017) · Oncogene · doi:10.1038/onc.2017.233 · Cited by 45
Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis
Sato, N., Koinuma, J., Ito, T., Tsuchiya, E., Kondo, S., Nakamura, Y., & Daigo, Y. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20747 · Cited by 43
Dai, C. S., Chung, Y.-M., Kovac, E. Z., Zhu, Z., Li, J., Magi‐Galluzzi, C., Stephenson, A. J., Klein, E. A., & Sharifi, N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1313 · Cited by 43
Geybels, M. S., Fang, M., Wright, J. L., Qu, X., Bibikova, M. V., Klotzle, B., Fan, J., Feng, Z., Ostrander, E. A., Nelson, P. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20940 · Cited by 43
Pandey, P., Seshacharyulu, P., Das, S., Rachagani, S., Ponnusamy, M. P., Yan, Y., Johansson, S. L., Datta, K., Lin, M. F., & Batra, S. K. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.160 · Cited by 42
Xie, J., Erneux, C., & Pirson, I. (2013) · BioEssays · doi:10.1002/bies.201200168 · Cited by 38
Amino acid and small GTPase regulation of mTORC1
Nguyen, T. P., Frank, A. R., & Jewell, J. L. (2017) · Cellular Logistics · doi:10.1080/21592799.2017.1378794 · Cited by 38
PTEN loss and activation of K‐RAS and β‐catenin cooperate to accelerate prostate tumourigenesis
Jefferies, M. T., Cox, A. C., Shorning, B. Y., Méniel, V. S., Griffiths, D. F. R., Kynaston, H., Smalley, M. J., & Clarke, A. R. (2017) · The Journal of Pathology · doi:10.1002/path.4977 · Cited by 37
Self-citationToren, P., Kim, S., Johnson, F. D., & Zoubeidi, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152861 · Cited by 35
Patel, R., Brzezińska, E. A., Repiscak, P., Ahmad, I., Mui, E., Gao, M.-L., Blomme, A., Harle, V., Tan, E., Malviya, G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1684 · Cited by 35
Munkley, J., Livermore, K. E., McClurg, U. L., Kalna, G., Knight, B., McCullagh, P. J., McGrath, J. S., Crundwell, M. C., Leung, H. Y., Robson, C. N., et al. (2015) · Oncoscience · doi:10.18632/oncoscience.243 · Cited by 34
Cullin 3 mediates SRC-3 ubiquitination and degradation to control the retinoic acid response
Ferry, C., Gaouar, S., Fischer, B., Boeglin, M., Paul, N., Samarut, E., Piskunov, A., Pankotai-Bodo, G., Brino, L., & Rochette-Egly, C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102572108 · Cited by 33
Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature.
Giacinti, S., Bassanelli, M., Aschelter, A. M., Milano, A., Roberto, M., & Marchetti, P. (2014) · PubMed · Cited by 33
PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models
Ellwood‐Yen, K., Keilhack, H., Kunii, K., Dolinski, B. M., Connor, Y., Hu, K., Nagashima, K., O’Hare, E., Erkul, Y., Bacco, A. D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2282 · Cited by 32
Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks
Malik, N., Macartney, T., Hornberger, A., Anderson, K. E., Tovell, H., Prescott, A. R., & Alessi, D. R. (2017) · Biochemical Journal · doi:10.1042/bcj20170650 · Cited by 32
Mavrommati, I., Cisse, O., Falasca, M., & Maffucci, T. (2016) · Scientific Reports · doi:10.1038/srep23277 · Cited by 31
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer
Heřmanová, I., Zúñiga-García, P., Caro‐Maldonado, A., Fernández‐Ruiz, S., Salvador, F., Martín-Martín, N., Zabala‐Letona, A., Núnez-Ollé, M., Torrano, V., Camacho, L., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191787 · Cited by 31
Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression
Bowen, C., Ostrowski, M. C., Leone, G. W., & Gelmann, E. P. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-4110 · Cited by 30
Bago, R., Sommer, E. M., Castel, P., Crafter, C., Bailey, F. P., Shpiro, N., Baselga, J. M., Cross, D. A. E., Eyers, P. A., & Alessi, D. R. (2016) · The EMBO Journal · doi:10.15252/embj.201670010 · Cited by 29
Rynkiewicz, N. K., Fedele, C. G., Chiam, K., Gupta, R., Kench, J. G., Ooms, L. M., McLean, C., Giles, G. G., Horvath, L. G., & Mitchell, C. A. (2014) · The Prostate · doi:10.1002/pros.22895 · Cited by 28
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma
Vallejo-Díaz, J., Olazabal-Morán, M., Cariaga-Martínez, A. E., Pajares, M. J., Flores, J. M., Pío, R., Montuenga, L. M., & Carrera, A. C. (2016) · Oncotarget · doi:10.18632/oncotarget.13195 · Cited by 28
Expression of phosphorylated-mTOR during the development of prostate cancer
Sutherland, S., Benito, R. P., Henshall, S. M., Horvath, L. G., & Kench, J. G. (2014) · The Prostate · doi:10.1002/pros.22840 · Cited by 27
Kwak, M. K., Johnson, D. T., Zhu, C., Lee, S. H., Ye, D., Luong, R. H., & Sun, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053476 · Cited by 27
Non-nuclear AR Signaling in Prostate Cancer
Zamagni, A., Cortesi, M., Zanoni, M., & Tesei, A. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00651 · Cited by 27
Phosphatidylinositolphosphate phosphatase activities and cancer
Rudge, S. A., & Wakelam, M. J. O. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r059154 · Cited by 25
Direct physical interaction of active Ras with mSIN1 regulates mTORC2 signaling
Lone, M. D., Miyan, J., Asif, M., Malik, S. A., Dubey, P., Singh, V., Singh, K., Mitra, K., Pandey, D., Haq, W., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6422-6 · Cited by 25
Troxell, M. L. (2012) · Journal of Clinical & Experimental Pathology · doi:10.4172/2161-0681.s1-002 · Cited by 24
LKB1 suppresses proliferation and invasion of prostate cancer through hedgehog signaling pathway.
Xu, P., Cai, F., Liu, X., & Guo, L. (2014) · Europe PMC (PubMed Central) · Cited by 23
Evren, S., Dermen, A., Lockwood, G. A., Fleshner, N. E., & Sweet, J. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200083 · Cited by 23
Han, R., Zhang, L., Gan, W., Fu, K., Jiang, K., Ding, J., Wu, J., Han, X., & Li, D. (2019) · The Prostate · doi:10.1002/pros.23786 · Cited by 23
Kladney, R. D., Cardiff, R. D., Kwiatkowski, D. J., Chiang, G. G., Weber, J. D., Arbeit, J. M., & Lu, Z. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1646 · Cited by 21
Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells
Catena, V., Bruno, T., Nicola, F. D., Goeman, F., Pallocca, M., Iezzi, S., Sorino, C., Cigliana, G., Floridi, A., Blandino, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12060 · Cited by 21
Role of Wnt signalling in advanced prostate cancer
Ahmad, I., & Sansom, O. J. (2018) · The Journal of Pathology · doi:10.1002/path.5029 · Cited by 18
Wingless/β-catenin signaling as a modulator of chemoresistance in cancer
Johnsen, J. I., Wickström, M., & Baryawno, N. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1131356 · Cited by 10
Co‐targeting driver pathways in prostate cancer: two birds with one stone
Zoubeidi, A., & Gleave, M. E. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201808928 · Cited by 6
Cited by
The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review
Rascio, F., Spadaccino, F., Rocchetti, M. T., Castellano, G., Stallone, G., Netti, G. S., & Ranieri, E. (2021) · Cancers · doi:10.3390/cancers13163949 · Cited by 497
Mafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 56
Metadata
- Authors
- Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-25
- Volume
- 21
- Issue
- 12
- Pages
- 4507
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3037348089
- Cited by
- 616
- References
- 366
- FWCI
- 20.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.